Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Late cornified envelope protein 3E (LCE3E) is a structural protein of the stratum corneum, the outermost layer of the skin, and a member of the LCE (late cornified envelope) protein family[2][5]. Expression of LCE3E is strongly upregulated in the skin after injury or in response to inflammatory cytokines, particularly in conditions such as psoriasis, where it participates in repair of the skin barrier[1]. While it does not serve as a direct pharmacological receptor or enzyme, deletions or dysregulation of genes in the LCE3 group (notably LCE3B and LCE3C, less directly LCE3E) have been associated with psoriasis risk[1]. LCE3E localizes to chromosome 1q21, within a gene cluster important for the skin barrier[2][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Late cornified envelope protein 3E (LCE3E).